State

Northern Mariana Islands product recalls

73,827 recalls have nationwide distribution and so reach Northern Mariana Islands. 23 additional recalls listed Northern Mariana Islands specifically in their distribution scope.

What the numbers show

Total: 23
Critical: 0
Severe: 18
Most recent: 2026-09-23

Of the 23 recalls naming Northern Mariana Islands we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 18 (78%) are Severe.

Which agencies issued them

These figures cover only the 23 recalls whose distribution notice names Northern Mariana Islands specifically. The 73,827 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

54026–54050 of 73850

SevereFDA (Drugs)·D-560-2015·2015-04-29
Carbazochrome API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Carbazochrome active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Carbazochrome active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-685-2015·2015-04-29
Fluphenazine Decanoate Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Fluphenazine Decanoate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Fluphenazine Decanoate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-710-2015·2015-04-29
Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-499-2015·2015-04-29
Acetazolamide API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Acetazolamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Acetazolamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-907-2015·2015-04-29
Attix Pharmaceuticals Recalls Sulfathiazole Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Sulfathiazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed to compounding pharmacies and research organizations.
Product
Sulfathiazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-649-2015·2015-04-29
Attix Pharmaceuticals Recalls Enzalutamide API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling enzalutamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Enzalutamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-920-2015·2015-04-29
Terbinafine Base Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Terbinafine Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Terbinafine Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-754-2015·2015-04-29
Attix Pharmaceuticals Recalls Levetiracetam Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Levetiracetam active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Levetiracetam active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-918-2015·2015-04-29
Attix Pharmaceuticals Recalls Temozolomide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Temozolomide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Temozolomide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-854-2015·2015-04-29
Attix Pharmaceuticals Recalls Prazosin HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Prazosin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Prazosin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-933-2015·2015-04-29
Tobramycin Sulfate Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Tobramycin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Tobramycin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-629-2015·2015-04-29
Attix Pharmaceuticals Recalls Diclofenac Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Diclofenac Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Diclofenac Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-580-2015·2015-04-29
Attix Pharmaceuticals Recalls Chloroxine Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Chloroxine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Chloroxine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-802-2015·2015-04-29
Attix Pharmaceuticals Recalls Misoprostol API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Misoprostol 1% active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Misoprostol 1% active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-955-2015·2015-04-29
Attix Pharmaceuticals Recalls Voriconazole Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Voriconazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Voriconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-566-2015·2015-04-29
Attix Pharmaceuticals Recalls Cefadroxil Monohydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cefadroxil Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Cefadroxil Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-607-2015·2015-04-29
Attix Pharmaceuticals Recalls Cyclosporine A Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cyclosporine A active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Cyclosporine A active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-559-2015·2015-04-29
Attix Pharmaceuticals Recalls Capecitabine Due to Penicillin Cross Contamination
Attix Pharmaceuticals is recalling capecitabine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Capecitabine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-501-2015·2015-04-29
Attix Pharmaceuticals Recalls Acyclovir Sodium Due to Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Acyclovir Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Acyclovir Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-810-2015·2015-04-29
Attix Pharmaceuticals Recalls Mycophenolate Mofetil Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Mycophenolate Mofetil active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Mycophenolate Mofetil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-568-2015·2015-04-29
Attix Pharmaceuticals Recalls Cefixime API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cefixime active pharmaceutical ingredient (API) due to potential penicillin cross-contamination from inadequate facility separation.
Product
Cefixime active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-750-2015·2015-04-29
Leflunomide API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Leflunomide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Leflunomide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-787-2015·2015-04-29
Attix Pharmaceuticals Recalls Methscopolamine Bromide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Methscopolamine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Methscopolamine Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-640-2015·2015-04-29
Attix Pharmaceuticals Recalls Doxorubicin HCI Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Doxorubicin HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.
Product
Doxorubicin HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-641-2015·2015-04-29
Attix Pharmaceuticals Recalls Doxycycline HCI Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Doxycycline HCI active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Doxycycline HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide